Neotis

Neotis is a French biotechnology company focused on developing immunotherapies to treat age-related and fibrotic diseases by targeting and eliminating pathogenic senescent cells. Leveraging its proprietary computational platform, NTS, the company maps the surfaceome of fibrotic tissues to identify highly specific transmembrane targets unique to aging and damaged tissues. Neotis's lead program is focused on idiopathic pulmonary fibrosis (IPF), where it utilizes bispecific T-cell engagers (TCEs) to selectively deplete aberrant basaloid cells (ABCs) that drive fibrotic scarring. Spun out of research from the Institut Curie and AP-HP, the company aims to halt disease progression rather than merely slowing symptoms.